---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-101971"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:29:16.735065+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH

## Summary
- Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.
- Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.
- Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.
- Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations.

## SEC filing metadata
- accession: 0000950170-25-101971
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/0000950170-25-101971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025101971/itrm-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-101971
- JSON: https://secwatch.observer/filing/0000950170-25-101971.json
- Plain text: https://secwatch.observer/filing/0000950170-25-101971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.